VEEVBy Calypso Research8 min read

Veeva Systems (VEEV) Q4 2025 Earnings Analysis

VEEV Rises 4.0% as Veeva Systems Posts Another Strong Quarter

Key Takeaways

Veeva Systems (VEEV) reported Q4 2025 earnings with revenue of $836M, representing a +16.0% year-over-year change. The stock moved +4.0% on earnings day.

The bull case: Veeva’s deep domain position in life sciences, expanding R&D and safety platforms, and early but credible AI and agentic applications create a long runway for durable double-digit growth and margin resilience as customers standardize on its ecosystem.

The bear case: Slower-than-hyped AI monetization, potential execution and migration risks in Vault CRM and EDC, tougher Crossix comps, and maturing commercial segments could cap growth and pressure the premium valuation if new products and AI agents fail to inflect demand as quickly as hoped.

Financial Highlights

  • Revenue: $836M (+16.0% YoY)
  • Gross Profit: $622M (74.5% margin, -0.4% YoY)
  • Operating Income: $246M (29.4% margin, +3.3% YoY)
  • Net Income: $244M
  • TTM Revenue: $3.2B

Stock Performance

  • Earnings Day Move: +4.0%
  • Year-to-Date: -10.7%
  • 1-Year Return: -10.9%
  • vs. S&P 500 (since earnings): -22.3%
  • vs. Nasdaq (since earnings): -20.2%

View live VEEV data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Veeva Systems's Q4 2025 earnings call:

Role of AI in Veeva’s Strategy, Product Roadmap, and Customer Adoption

Sentiment: Positive

"AI is -- really, the goal there is automation, right? That's the goal. But AI is not the only way you do automation... So it's a driver, but I wouldn't say it's a major driver." — Peter Gassner
"AI is not replacing software. That's just not happening... these core systems, they're essential... we'll add core AI systems, as will SAP, as will Workday... we're really in these early days of AI and people get a lot of hyper and they think it's going to play out over 1 or 2 months. It's not. It's going to play out over 10 or 20 years." — Peter Gassner

Vault CRM Transition, Top‑20 Win Rates, and Salesforce Displacement Risk

Sentiment: Positive

"We have close to 140 customers live on Vault CRM... So we've proven that this is the fastest path to get to CRM and agentic CRM... I don't see any risk there. I think actually, there's a greater risk that a customer that decided to do Salesforce and tries to go down the path of a custom build project... see how difficult it is and come back to Veeva." — Paul Shawah
"Those top -- those 10 customers that have picked us, all those projects were started and they're all going. And they're all going to a very stable product that's already live... Now on the other hand, not all of Salesforce projects are going so well... they're coding basically a custom solution... there may be a new regime in, and they might not want that custom build. So there's a complete difference in certainty." — Peter Gassner

Growth Durability and Mix in R&D Cloud (EDC, RTSM, Safety, Study‑by‑Study / CRO Channel)

Sentiment: Positive

"RTSM is a significant product area. You could think of it as significant as the EDC area... We're not a small stand-alone RTSM vendor. We're a big Veeva that has a lot of scale and flex, but we have an outstanding stand-alone RTSM product... it's a milestone deal for Veeva and for the industry." — Peter Gassner
"I would say, yes, hit a bit of an air pocket there in the EDC, and that's just the random timings of life, I guess... Our competitive environment has never been stronger... do you complete that in 5 years, in 7 years? When does the EDC breakthrough come? Does it come in 2 years or 1 year or 4 years? Those things are hard to predict... but we have a structural advantage." — Peter Gassner

AI’s Impact on Life Sciences Outcomes, Safety, and Clinical / Commercial Workflows

Sentiment: Positive

"The biggest bottleneck by far is there's a patient somewhere out there in the world... When did they get the right medicine that will best treat them? That's where 90% of the value in life sciences is lost... AI doctors and large language models can help bridge that gap... maybe that 90% inefficiency goes down to 50%, and that will be a tremendous boom." — Peter Gassner
"In safety, it's just very clear. It's about replacing that type of labor with automation, with AI software... what does make that market slow is people are very reluctant to change their core safety database... it's a big deal for a pharmaceutical company if your products get pulled off the market. So that's -- these things are very critical." — Peter Gassner

Near‑Term Growth Outlook, Crossix Sustainability, and Subscription vs. Billings Dynamics

Sentiment: Mixed

"Crossix had an outstanding year last year, and it certainly exceeded our expectations... The compares do get tougher, but that is a business that's executing really well with a long runway for growth. And so we continue to expect very healthy growth from the Crossix team." — Brian Van Wagener
"As you think about subs growth in '27... we've got a little bit of slowing growth in commercial... In R&D, you'll see that the growth rate shifts a bit, and that's really driven by the shift from growth coming from our mature products like eTMF to the really big new products like RTSM and EDC and safety and LIMS... you're primarily seeing the effect of that mix shift in the delta there between subs and billings." — Brian Van Wagener

Bull Case

Veeva’s deep domain position in life sciences, expanding R&D and safety platforms, and early but credible AI and agentic applications create a long runway for durable double-digit growth and margin resilience as customers standardize on its ecosystem.

Bear Case

Slower-than-hyped AI monetization, potential execution and migration risks in Vault CRM and EDC, tougher Crossix comps, and maturing commercial segments could cap growth and pressure the premium valuation if new products and AI agents fail to inflect demand as quickly as hoped.

Looking Ahead

With revenue growing +16.0% year-over-year, the key question is whether Veeva Systems can sustain this growth trajectory, particularly around role of AI in Veeva’s Strategy, Product Roadmap, and Customer Adoption. With operating margins at 29.4%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Veeva Systems's revenue in Q4 2025?

Veeva Systems reported Q4 2025 revenue of $836M, representing a +16.0% year-over-year change.

Did Veeva Systems beat earnings expectations in Q4 2025?

The stock rose +4.0% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Veeva’s deep domain position in life sciences, expanding R&D and safety platforms, and early but credible AI and agentic applications create a long runway for durable double-digit growth and margin resilience as customers standardize on its ecosystem.

What is the bull case for VEEV stock?

The bull case for VEEV centers on: Veeva’s deep domain position in life sciences, expanding R&D and safety platforms, and early but credible AI and agentic applications create a long runway for durable double-digit growth and margin resilience as customers standardize on its ecosystem.

What is the bear case for VEEV stock?

The bear case for VEEV centers on: Slower-than-hyped AI monetization, potential execution and migration risks in Vault CRM and EDC, tougher Crossix comps, and maturing commercial segments could cap growth and pressure the premium valuation if new products and AI agents fail to inflect demand as quickly as hoped.

How has VEEV stock performed since its Q4 2025 earnings?

VEEV moved +4.0% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +22.3% since earnings. Year-to-date, the stock has returned -10.7%.

Browse all 400+ earnings reports →

Learn More

Analyze VEEV in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Veeva Systems and 400+ other stocks, explore the full platform.

Open VEEV on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.